WO2011107150A1 - Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats - Google Patents

Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats Download PDF

Info

Publication number
WO2011107150A1
WO2011107150A1 PCT/EP2010/052728 EP2010052728W WO2011107150A1 WO 2011107150 A1 WO2011107150 A1 WO 2011107150A1 EP 2010052728 W EP2010052728 W EP 2010052728W WO 2011107150 A1 WO2011107150 A1 WO 2011107150A1
Authority
WO
WIPO (PCT)
Prior art keywords
meloxicam
cats
renal
pharmacologically acceptable
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/052728
Other languages
French (fr)
Inventor
Richard Gowan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH filed Critical Boehringer Ingelheim Vetmedica GmbH
Priority to KR1020127025827A priority Critical patent/KR20130037237A/en
Priority to SG2012064663A priority patent/SG183846A1/en
Priority to US13/581,661 priority patent/US9149480B2/en
Priority to BR112012022073A priority patent/BR112012022073A2/en
Priority to PCT/EP2010/052728 priority patent/WO2011107150A1/en
Priority to MX2012010077A priority patent/MX2012010077A/en
Priority to CA2791805A priority patent/CA2791805A1/en
Priority to AU2010347598A priority patent/AU2010347598B2/en
Publication of WO2011107150A1 publication Critical patent/WO2011107150A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention is directed to the long-term use of meloxicam to treat musculoskeletal disorders in cats with and without pre-existing renal disease without any negative effects on renal function.
  • Meloxicam is the only molecule licensed for treatment of chronic musculoskeletal disorders in cats. These conditions affect the quality of life of cats and often require treatment. Impaired renal function is currently listed as a contraindication on NSAID data sheets.
  • chronic renal disease and chronic musculoskeletal disorders such as osteoarthritis (OA) are common in elderly cats and often coexist.
  • Osteoarthritis affects synovial joints, associated with loss of cartilage, inflammation, bone remodelling and formation of osteophytes. It is usually idiopathic and primarily affects elbow joints and hips.
  • Clinical signs include for example difficulty in jumping, lameness, stiffness as well as behavioural changes such as demeanour, reduced grooming and resentment of handling.
  • meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base thereof may be used for the long-term treatment of musculoskeletal disorders in cats, especially aged cats, with or without pre-existing renal disease, without having any negative effect on renal functions in cats during a treatment from 10 to 40 months or more.
  • the invention related to the use of meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base thereof for the preparation of a veterinary medical composition having analgesic efficacy for the long-term treatment of musculoskeletal disorders such as but not limiting to osteoarthritis in cats, particularly in older cats, without having any negative effects on renal functions during a treatment from 10 to 40 months or more. Treatment with such a formulation will not accelerate already existing renal diseases in older cats, nor initiate any renal disease.
  • the pharmacologically acceptable meloxicam salt comprises the meglumine, potassium or ammonium salt, preferably the meloxicam meglumine salt.
  • the present invention provides a formulation containing meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base, one or more vehicles, and optionally one or more suitable additives, for the long term treatment of musculoskeletal disorders in cats, characterised in that no negative effects on renal function occur during a treatment from 10 to 40 months or more. Further the invention relates to the use of a formulation containing meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more vehicles for preparing a veterinary medical composition having analgesic efficacy for the long-term treatment of musculoskeletal disorders in cats, characterised in that no negative effects on renal function occur during a treatment from 10 to 40 months or more.
  • Said formulation contains or essentially consists of meloxicam or a pharmacologically acceptable salt thereof, water, optionally one or more additives selected from group of consisting of buffers, solubilisers, preservatives and optionally thickeners.
  • the musculoskeletal disease comprises but not limited to osteoarthritis.
  • the treatment occurs over a long-term period of at least 6 months, preferred ranges are selected from the group selected of 10 to 40 months, 10 to 37 months, 10 to 30 months, 10 to 25 months, 10 to 20 months, 10 to 17 months,
  • Older cats or aged cats are herein defined as being 5 years old or older, preferably from 5 to 20 years, even more preferably from 7 to 17 years, especially preferred from 10 to 13.4 to 15.5 to 16 years.
  • Renal diseases may include acquired renal diseases such as chronic tubulo-interstitial nephritis, glomerulonephritis, pyelonephritis, amyloidosis, hydronephrosis, renal lymphoma or congenital diseases that cause kidney failure in cats such as polycystic kidney disease, renal aplasia, renal hypoplasia, renal dysplasia, amyloidosis. These may or may not be in a chronic disease state. However, the treatment is also appropriate for cats over 5 years of age without any preexisting renal diseases.
  • the treatment of cats may be performed in a formulation useful for cats that are 5 years or older.
  • the daily dose of the formulation is between 0.01 and 0.075 mg/kg daily, preferably 0.05 mg/kg.
  • the lowest effective dose for a median maintenance dose was found to be 0.02 mg/kg.
  • This range can be used to treat musculoskeletal disease such as osteoarthritis.
  • the musculoskeletal disease is a chronic disease.
  • the formulation contains or essentially consists of meloxicam salt, water, optionally one or more additives selected from the group consisting of buffers, solubilisers, preservatives and optionally thickeners.
  • the medical records of a feline-only practice were searched for cats with OA being treated with meloxicam during a 4 year period.
  • a diagnosis of OA was based upon any two of the following: owner noted mobility changes and/ or physical examination findings or radiographic changes.
  • Cats included were older than 7 years and treated with meloxicam for a duration of more than 6 months.
  • Complete medical records were available for review. Biochemistry, urinalysis and body weight were regularly monitored. The progression of renal disease in the aged non-renal and renal group treated was compared to age matched and IRIS matched untreated controls from the same clinic.
  • meloxicam can be used as a treatment for aged cats with painful musculoskeletal disorders and concurrent renal disease.
  • the aged cats treated with NSAID therapy shall be carefully monitored.
  • IRIS stage 1 Inadequate concentrating ability, abnormal renal palpation. Creatinine ⁇ 140 ⁇ / ⁇ ( ⁇ 1.6 mg/dL)
  • IRIS stage 2 Mild or absent clinical signs associated with renal disease. Creatinine 140-250 ⁇ / ⁇ (1.6-2.8 mg/dL)
  • the treated cats were then subdivided into two groups: the renal treated group that belonged to IRIS stage 1 -3 and were pre-treated, and the non-renal treated group that has no identifiable renal disease pre-treatment.
  • Urine specific gravity, serum creatinine and bodyweight were used as indicators of renal disease progression. The progression of renal disease was then compared to age and IRIS matched untreated controls were then randomly identified from the database of the same clinic.
  • the median age of the renal and non-renal treated cats, median treatment duration and median maintenance dose was calculated.
  • the progression of renal disease in the non-renal treated group was compared to the age matched untreated controls.
  • the progression of renal disease in the treated renal-diseased group was compared to age matched and IRIS matched untreated controls from the same clinic.
  • Statistical analysis was carried out using a time adjusted area-under-the-curve (AUC) changes from baseline time 0 until the last recorded value (n).
  • AUC area-under-the-curve
  • the Wilcoxon rank-sum-test was used to compare the groups. With this nonparametric test the distribution of the adjusted AUC of two groups was compared regarding the location. Under the null hypothesis it is assumed that there is no location shift in the distributions of the two treatment groups. If the resulting p-value is lower than the two-sided significance level of 5 % the null hypothesis is rejected.
  • the median treatment duration was 527 days in the renal group and 400 days in the non-renal group. After dose titration to the lowest effective dose, the median maintenance dose was 0.02 mg/kg daily in both the renal treated and non-renal treated groups. There were no differences in the progression of renal parameters in the renal group treated with meloxicam versus the age and IRIS matched untreated renal group or the non-renal group treated with meloxicam versus the non- renal group not treated with meloxicam.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention is directed to the use of a formulation comprising meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base thereof for the long-term treatment of musculoskeletal disorders in cats. No negative effects on renal function occur following a treatment from 10 to 20 months or more.

Description

Use of Meloxicam for the Long-term Treatment of Musculoskeletal
Disorders in Cats
FIELD OF THE INVENTION
The present invention is directed to the long-term use of meloxicam to treat musculoskeletal disorders in cats with and without pre-existing renal disease without any negative effects on renal function.
BACKGROUND OF THE INVENTION
Meloxicam is the only molecule licensed for treatment of chronic musculoskeletal disorders in cats. These conditions affect the quality of life of cats and often require treatment. Impaired renal function is currently listed as a contraindication on NSAID data sheets. However, chronic renal disease and chronic musculoskeletal disorders, such as osteoarthritis (OA) are common in elderly cats and often coexist. Osteoarthritis affects synovial joints, associated with loss of cartilage, inflammation, bone remodelling and formation of osteophytes. It is usually idiopathic and primarily affects elbow joints and hips. Clinical signs include for example difficulty in jumping, lameness, stiffness as well as behavioural changes such as demeanour, reduced grooming and resentment of handling.
Meloxicam was licensed for long-term use in cats in 2007 at an oral dose of 0.1 mg/ kg on day 1 followed by 0.05 mg/ kg. However, there is no prior art that demonstrates that the use of meloxicam is appropriate for long-term treatment of feline. It is reported by Gunew that feline suffering from osteoarthritis can be treated with meloxicam in a concentration range between 0.01 - 0.03 mg/ kg. (Gunew et al., Long-term safety, efficacy and palatability of oral meloxicam at 0.01 - 0.03 mg/ kg for treatment of osteoarthritic pain in cats. Journal of Feline Medicine and Surgery 2008, 10, 235-241 ) The trials were completed after a mean treatment duration of 5.8 months. However, since this study does not include any comparable placebo product and uses subjectivemeasurements only, its conclusions are questionable. A short-term (23 days) concept study performed by Clarke & Bennett has also shown that a daily meloxicam dosage of 0.05 mg/ cat can be used to treat osteoarthritis. (Clarke & Bennett, Feline osterarthritis: a prospective study of 28 cases. Journal of Small Animal Practice 2006, 47, 439-445) This study does not include any thorough investigation and assessment of meloxicam treatment over a longer period of time.
Therefore, it is an object of the present invention to develop a long-term treatment of musculoskeletal disorders in cats, especially aged cats, with and without pre-existing renal disease and without accelerating the progression of renal diseases in cats.
DESCRIPTION OF THE INVENTION
Surprisingly, it has been found that meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base thereof may be used for the long-term treatment of musculoskeletal disorders in cats, especially aged cats, with or without pre-existing renal disease, without having any negative effect on renal functions in cats during a treatment from 10 to 40 months or more.
Thus, the invention related to the use of meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base thereof for the preparation of a veterinary medical composition having analgesic efficacy for the long-term treatment of musculoskeletal disorders such as but not limiting to osteoarthritis in cats, particularly in older cats, without having any negative effects on renal functions during a treatment from 10 to 40 months or more. Treatment with such a formulation will not accelerate already existing renal diseases in older cats, nor initiate any renal disease. According to the invention the pharmacologically acceptable meloxicam salt comprises the meglumine, potassium or ammonium salt, preferably the meloxicam meglumine salt.
The present invention provides a formulation containing meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base, one or more vehicles, and optionally one or more suitable additives, for the long term treatment of musculoskeletal disorders in cats, characterised in that no negative effects on renal function occur during a treatment from 10 to 40 months or more. Further the invention relates to the use of a formulation containing meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more vehicles for preparing a veterinary medical composition having analgesic efficacy for the long-term treatment of musculoskeletal disorders in cats, characterised in that no negative effects on renal function occur during a treatment from 10 to 40 months or more. Said formulation contains or essentially consists of meloxicam or a pharmacologically acceptable salt thereof, water, optionally one or more additives selected from group of consisting of buffers, solubilisers, preservatives and optionally thickeners.
Meloxicam or a pharmacologically acceptable salt thereof for the long-term treatment of musculoskeletal disorders in cats having a pre-existing renal disease or having no pre-existing renal disease. Further, the invention relates to meloxicam or a pharmacologically acceptable salt thereof for the long-term treatment of musculoskeletal disorders in cats with chronic kidney disease. The musculoskeletal disease comprises but not limited to osteoarthritis.
The treatment occurs over a long-term period of at least 6 months, preferred ranges are selected from the group selected of 10 to 40 months, 10 to 37 months, 10 to 30 months, 10 to 25 months, 10 to 20 months, 10 to 17 months,
1 1 to 40 months, 1 1 to 37 months, 1 1 to 30 months, 1 1 to 25 months, 1 1 to 20 months, 1 1 to 17 months, 12 to 40 months, 12 to 37 months, 12 to 30 months,
12 to 25 months, 12 to 20 months, 12 to 17 months, 13 to 40 months, 13 to 37 months, 13 to 30 months, 13 to 25 months, 13 to 20 months, 13 to 17 months, 14 to 40 months, 14 to 37 months, 14 to 30 months, 14 to 25 months, 14 to 20 months and 14 to 17 months.
Older cats or aged cats are herein defined as being 5 years old or older, preferably from 5 to 20 years, even more preferably from 7 to 17 years, especially preferred from 10 to 13.4 to 15.5 to 16 years. Studies have shown that 53 % of cats over 7 years of age have renal diseases. Renal diseases may include acquired renal diseases such as chronic tubulo-interstitial nephritis, glomerulonephritis, pyelonephritis, amyloidosis, hydronephrosis, renal lymphoma or congenital diseases that cause kidney failure in cats such as polycystic kidney disease, renal aplasia, renal hypoplasia, renal dysplasia, amyloidosis. These may or may not be in a chronic disease state. However, the treatment is also appropriate for cats over 5 years of age without any preexisting renal diseases.
In another embodiment the treatment of cats may be performed in a formulation useful for cats that are 5 years or older. The daily dose of the formulation is between 0.01 and 0.075 mg/kg daily, preferably 0.05 mg/kg. The lowest effective dose for a median maintenance dose was found to be 0.02 mg/kg. This range can be used to treat musculoskeletal disease such as osteoarthritis. The musculoskeletal disease is a chronic disease. The formulation contains or essentially consists of meloxicam salt, water, optionally one or more additives selected from the group consisting of buffers, solubilisers, preservatives and optionally thickeners.
Example
The medical records of a feline-only practice were searched for cats with OA being treated with meloxicam during a 4 year period. A diagnosis of OA was based upon any two of the following: owner noted mobility changes and/ or physical examination findings or radiographic changes. Cats included were older than 7 years and treated with meloxicam for a duration of more than 6 months. Complete medical records were available for review. Biochemistry, urinalysis and body weight were regularly monitored. The progression of renal disease in the aged non-renal and renal group treated was compared to age matched and IRIS matched untreated controls from the same clinic.
These results prove that a maintenance dose of 0.02 mg/kg meloxicam does not hasten progression of renal disease in aged cats or aged cats with pre- existent stable IRIS stage 1-3 renal disease. Therefore meloxicam can be used as a treatment for aged cats with painful musculoskeletal disorders and concurrent renal disease. The aged cats treated with NSAID therapy shall be carefully monitored.
Materials and Methods The database of a feline-only practice in suburban Melbourne was searched for cats which had been treated for chronic musculoskeletal disorders with meloxicam (Metacam oral suspension, Boehringer Ingelheim) during a 4 year period. The diagnosis of osteoarthritis or spondylosis deformans had been made based upon any two of the following: owner noted mobility changes, physical examination findings or radiographic changes. The inclusion criteria included cats greater than 7 years old which had been treated continuously with meloxicam for a duration of more than 6 months and which had complete medical records available for review. In addition, cats were only included if serum biochemistry, urine analysis and body weight had been regularly monitored.
Young cats were excluded, as were cats with no pre-treatment renal parameter measurements. In addition cats were also excluded if the owner could not be contacted to check that the cats were still receiving daily treatment with meloxicam. Age, breed, sex, concomitant diseases and medications as well as date treatment commenced, treatment duration and daily dose of meloxicam were recorded. The presence or absence of pre-treatment renal disease and staging of the renal disease was carried out using plasma creatinine and urine specific gravity according to the following recognised International Renal Interest Society criteria (IRIS staging 2006):
www.iris-kidnev.com
IRIS stage 1 : Inadequate concentrating ability, abnormal renal palpation. Creatinine < 140 μηιοΙ/Ι (< 1.6 mg/dL)
IRIS stage 2: Mild or absent clinical signs associated with renal disease. Creatinine 140-250 μηιοΙ/Ι (1.6-2.8 mg/dL)
IRIS stage 3: Many clinical signs present. Creatinine 251-440 μηηοΙ/Ι (2.8-5 mg/dL)
The treated cats were then subdivided into two groups: the renal treated group that belonged to IRIS stage 1 -3 and were pre-treated, and the non-renal treated group that has no identifiable renal disease pre-treatment. Urine specific gravity, serum creatinine and bodyweight were used as indicators of renal disease progression. The progression of renal disease was then compared to age and IRIS matched untreated controls were then randomly identified from the database of the same clinic.
Statistical Analysis
The median age of the renal and non-renal treated cats, median treatment duration and median maintenance dose was calculated. The progression of renal disease in the non-renal treated group was compared to the age matched untreated controls. The progression of renal disease in the treated renal-diseased group was compared to age matched and IRIS matched untreated controls from the same clinic. Statistical analysis was carried out using a time adjusted area-under-the-curve (AUC) changes from baseline time 0 until the last recorded value (n).
Figure imgf000008_0001
t0: time point of first measurement (baseline)
tn: time point of last measurement
C,: difference of parameter concentration at time point i=0,...,n to baseline
The Wilcoxon rank-sum-test was used to compare the groups. With this nonparametric test the distribution of the adjusted AUC of two groups was compared regarding the location. Under the null hypothesis it is assumed that there is no location shift in the distributions of the two treatment groups. If the resulting p-value is lower than the two-sided significance level of 5 % the null hypothesis is rejected.
Results
Out of a total database of 3016 cats, 214 cats which had been treated with Metacam® oral suspension were identified. Of these, 38 cats met the inclusion criteria for the treated group. 22 cats of these cats (58%) had IRIS stage 1-3 renal disease prior to treatment, whereof 8 cats were categorized to fit IRIS stage 1 , 13 cats belonged to stage 2 and 1 cat was classified to belong to stage 3. 16 cats had no identifiable renal disease prior to treatment. The median age of the renal treated group was 15.5 years and the non-renal treated group was 13.4 years.
The median treatment duration was 527 days in the renal group and 400 days in the non-renal group. After dose titration to the lowest effective dose, the median maintenance dose was 0.02 mg/kg daily in both the renal treated and non-renal treated groups. There were no differences in the progression of renal parameters in the renal group treated with meloxicam versus the age and IRIS matched untreated renal group or the non-renal group treated with meloxicam versus the non- renal group not treated with meloxicam.
Two renal-treated cats were excluded from analysis of creatinine changes from baseline as their pre-treatment sample was not carried out within 3 days of the start of treatment. There were no statistically significant differences in weight loss or the loss of urine concentrating ability in the renal group treated with meloxicam versus the age and IRIS matched untreated renal group or the nonrenal group treated with meloxicam versus the non- renal group not treated with meloxicam. Mean serum creatinine concentration increased statistically significantly less over time in the renal group treated with meloxicam than in the renal untreated group.
Example
The following formulation may be used according to the invention but not limited to:
1 ) Metacam® Suspension Boehringer Ingelheim for Cats

Claims

Claims
1. Meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base thereof for the long-term treatment of musculoskeletal disorders in cats, characterised in that no negative effects on renal function occur during a treatment from 10 to 40 months or more.
2. Meloxicam or a pharmacologically acceptable salt thereof according to claim 1 , characterised in that the cats have a pre-existing renal disease.
3. Meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 2, characterised in that the cats have no pre-existing renal disease
4. Meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 3, characterised in that the cats have a chronic kidney disease.
5. Meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 4, characterised in that the daily dose is from 0.01 and 0.075 mg/kg daily.
6. Meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 5, characterised in that the daily dose is from 0.02 to 0.06 mg/kg daily.
7. Meloxicam or a pharmacologically acceptable meloxicam salt thereof according to any one of claims 1 to 6, characterised in that the daily dose is 0.05 mg/kg daily.
8. Meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 7, characterised in that the musculoskeletal disease is osteoarthritis.
9. Meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 8, characterised in that the musculoskeletal disease is a chronic disease.
10. A formulation containing meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more vehicles for the long-term treatment of musculoskeletal disorders in cats, characterised in that no negative effects on renal function occur during a treatment from 10 to 40 months or more.
1 1. A formulation according to claim 10, characterised in that it contains or essentially consists of meloxicam salt, water, optionally one or more additives selected from the group consisting of buffers, solubilizers, preservatives and optionally thickeners.
PCT/EP2010/052728 2010-03-03 2010-03-03 Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats Ceased WO2011107150A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020127025827A KR20130037237A (en) 2010-03-03 2010-03-03 Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
SG2012064663A SG183846A1 (en) 2010-03-03 2010-03-03 Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US13/581,661 US9149480B2 (en) 2010-03-03 2010-03-03 Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
BR112012022073A BR112012022073A2 (en) 2010-03-03 2010-03-03 use of meloxicam for the long-term treatment of musculoskeletal disorders in cats.
PCT/EP2010/052728 WO2011107150A1 (en) 2010-03-03 2010-03-03 Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
MX2012010077A MX2012010077A (en) 2010-03-03 2010-03-03 Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats.
CA2791805A CA2791805A1 (en) 2010-03-03 2010-03-03 Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
AU2010347598A AU2010347598B2 (en) 2010-03-03 2010-03-03 Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/052728 WO2011107150A1 (en) 2010-03-03 2010-03-03 Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats

Publications (1)

Publication Number Publication Date
WO2011107150A1 true WO2011107150A1 (en) 2011-09-09

Family

ID=42238562

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/052728 Ceased WO2011107150A1 (en) 2010-03-03 2010-03-03 Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats

Country Status (8)

Country Link
US (1) US9149480B2 (en)
KR (1) KR20130037237A (en)
AU (1) AU2010347598B2 (en)
BR (1) BR112012022073A2 (en)
CA (1) CA2791805A1 (en)
MX (1) MX2012010077A (en)
SG (1) SG183846A1 (en)
WO (1) WO2011107150A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066955B2 (en) 2002-10-25 2015-06-30 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9943486B2 (en) 2010-05-05 2018-04-17 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US9956288B2 (en) 2000-06-20 2018-05-01 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions
US10548901B2 (en) 2004-02-23 2020-02-04 Boehringer Ingelheim Vetmedica Gmbh Meloxicam for the treatment of respiratory diseases in pigs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007135505A2 (en) * 2006-05-18 2007-11-29 Formevet S.P.A. Veterinary pharmaceutical compositions for the treatment of pain and inflammation
WO2008113149A2 (en) * 2007-03-22 2008-09-25 Ouro Fino Participações E Empreendimentos Ltda Observations where certain claims were found unsearchable

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2795529A (en) 1954-06-17 1957-06-11 American Home Prod Stabilized hyaluronidase solution containing calcium chloride
US3288675A (en) 1964-03-20 1966-11-29 Hoffmann La Roche Parenteral sulfonamide compositions and processes
JPS477352Y1 (en) 1969-06-13 1972-03-17
BE789726A (en) 1971-10-06 1973-04-05 Merck & Co Inc SUPPOSITORIES TO INDOMETHACIN
US3931212A (en) 1973-07-19 1976-01-06 Warner-Lambert Company Method for treating cardiovascular circulatory insufficiencies and hypotonia with 2-hydroxy-phenyl-1-oxa-4-azaspiroalkane derivatives
US3947576A (en) 1973-09-27 1976-03-30 Mortell Company Synergistic biostatic composition
DE2756113A1 (en) 1977-12-16 1979-06-21 Thomae Gmbh Dr K NEW 4-HYDROXY-2H-1,2-BENZOTHIAZINE-3-CARBOXAMIDE-1,1-DIOXIDES, THE PROCESS FOR THEIR MANUFACTURING AND THE MEDICINAL PRODUCTS CONTAINING THESE
FR2437838A1 (en) 1978-07-25 1980-04-30 Roecar Holdings Nv Prostaglandin inhibitors for benign adenoma of the prostate - includes salicylic, anthranilic and phenylacetic acid derivs., indole(s), indene(s), pyrrole(s) and pyrazolidine(s)
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
DE3217315C2 (en) 1982-05-08 1986-05-22 Gödecke AG, 1000 Berlin Medicinal preparations containing oxicam derivatives
US4543200A (en) 1983-09-28 1985-09-24 Sherman Laboratories, Inc. Contact lens preservative system cleaner and method
IT1212778B (en) 1983-10-07 1989-11-30 Lisapharma Spa PHARMACEUTICAL COMPOSITIONS ANTI-INFLAMMATORY AND / OR ANALGESIC ADAPTERITY, NON ULCEROGENE.
EP0173729B1 (en) 1984-03-14 1990-10-17 Jérôme CORBIERE Process for solubilizing active principles and pharmaceutical compositions thus obtained
DE3437232A1 (en) 1984-10-10 1986-04-17 Mack Chem Pharm STABILIZED INJECTION SOLUTIONS FROM PIROXICAM
IT1196307B (en) 1984-10-22 1988-11-16 Chiesi Farma Spa AQUEOUS PHARMACEUTICAL FORMULATIONS OF PIROXICAM MONOHYDRATE
IT1207994B (en) 1986-01-03 1989-06-01 Therapicon Srl WATER SOLUBLE SALTS OF ANTI-INFLAMMATORY AND ANALGESIC ADAPTITY COMPOUNDS, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS.
NL8600731A (en) 1986-03-21 1987-10-16 Dmv Campina Bv Improved spray-dried lactose and process for its preparation.
US4835187A (en) 1987-06-15 1989-05-30 American Home Products Corporation Spray dried ibuprofen
US5414011A (en) 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
DK174702B1 (en) 1987-09-11 2003-09-29 Syntex Llc Preservation system for ophthalmic formulations
IT1216686B (en) 1988-04-01 1990-03-08 Chiesi Farma Spa AQUEOUS PHARMACEUTICAL FORMULATIONS OF PIROXICAM AND PROCEDURE FOR THEIR PREPARATION.
EP0360246B1 (en) 1988-09-21 1994-03-30 G.D. Searle & Co. 3-Oxiranyl benzoic acids and derivatives thereof
US5360611A (en) 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
IL95942A0 (en) 1989-10-13 1991-07-18 Syntex Inc Collagen-containing ophthalmic formulation
KR920002148A (en) 1990-07-03 1992-02-28 안드레아 엘. 콜비 Pharmaceutical compositions for alleviating gastrointestinal symptoms caused by nonsteroidal anti-inflammatory drugs and methods for alleviating the same
US5824658A (en) 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
HU205550B (en) 1990-11-27 1992-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pyroxycam solution of increased stability, free from effects damaging tussues
FR2679135B1 (en) 1991-07-18 1995-05-19 Europhta Sa Laboratoire NOVEL OPHTHALMIC COMPOSITIONS WITH IMPROVED ADHESIVITY AND METHODS OF PREPARING THE SAME.
IT1251650B (en) 1991-10-29 1995-05-17 Boehringer Ingelheim Italia Inclusion compounds of meloxicam with cyclodextrin
US5654003A (en) 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
JP2860729B2 (en) 1992-03-10 1999-02-24 エスエス製薬株式会社 Planoprofen suspension syrup
DE4217971C1 (en) 1992-05-30 1993-10-21 Boehringer Ingelheim Vetmed Process and fluid bed apparatus for granulating and / or wrapping
US5455271A (en) 1992-06-18 1995-10-03 The Scripps Research Institute Tight-binding inhibitors of leukotriene A4 hydrolase
US8178516B2 (en) 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US5304561A (en) 1992-07-24 1994-04-19 Faezeh Sarfarazi New concept in glaucoma treatment
US5380934A (en) 1992-10-29 1995-01-10 Kyowa Hakko Kogyo Co., Ltd. Process for producing alanylgutamine
ES2065846B1 (en) 1993-04-20 1995-10-01 Cusi Lab PHARMACEUTICAL FORMULATION BASED ON A STEROID OR NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTIBIOTIC BELONGING TO THE GIRASE DNA INHIBITORS GROUP FOR ITS TOPICAL OPHTHALMIC USE.
DE4322826A1 (en) 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmaceutical preparation
US5676944A (en) 1993-10-06 1997-10-14 The Regents Of The University Of California Ocular therapy with homologous macrophages
US5474985A (en) 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
WO1995018604A1 (en) 1994-01-11 1995-07-13 Ciba-Geigy Ag Topical treatment of ocular photophobia
CN1129400A (en) 1994-05-06 1996-08-21 阿尔康实验室公司 Application of Vitamin E Tocopherol Derivatives in Ophthalmic Compositions
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5585492A (en) 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
JP3550782B2 (en) 1995-03-14 2004-08-04 大日本インキ化学工業株式会社 Expandable particles of lactic acid-based polyester
US5599535A (en) 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5674888A (en) 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
CN1196679A (en) 1995-07-19 1998-10-21 麦克公司 Method of treating colonic adenomas
EP0839029A1 (en) 1995-07-20 1998-05-06 PHARMACIA &amp; UPJOHN COMPANY Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules
NZ322588A (en) 1995-11-13 1999-01-28 Pitmy Int Nv An administration medium containing nitrous oxide for use in conjunction with analgesics, anti-inflammatories and anti-pyretics to enhance their action
US5686414A (en) 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
JP2000504723A (en) 1996-02-13 2000-04-18 ジー．ディー．サール アンド カンパニー Immunosuppressive effect of administration of cyclooxygenase-2 inhibitor and 5-lipoxygenase inhibitor
WO1997031631A1 (en) 1996-02-27 1997-09-04 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions
DK0934075T3 (en) 1996-06-20 2002-06-10 Novartis Ag Micrococcin antibiotic for the prevention and treatment of mastitis
DE59702733D1 (en) 1996-08-15 2001-01-11 Losan Pharma Gmbh EASILY SWALLOWABLE ORAL MEDICINE
ATA156496A (en) 1996-09-03 1997-10-15 Nycomed Austria Gmbh PHARMACEUTICAL COMPOSITION
US6071539A (en) 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
GB2318511A (en) 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
FR2765898B1 (en) 1997-07-10 1999-10-01 Thibierge Et Comar COLOR TRACK PAPER
DE19729879C2 (en) 1997-07-11 1999-07-08 Mann Gerhard Chem Pharm Fab Storage stable ophthalmic compositions comprising diclofenac and ofloxacin
CA2301304A1 (en) 1997-08-27 1999-03-04 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
JP4936579B2 (en) 1997-09-05 2012-05-23 第一三共株式会社 Loxoprofen-containing pharmaceutical preparation
CN1277550A (en) 1997-09-11 2000-12-20 尼科梅德丹麦有限公司 Compound composition for improved release of non-steroidal anti-inflammatory drugs (NSAIDs)
RS49982B (en) 1997-09-17 2008-09-29 Euro-Celtique S.A., SYNERGISTIC ANALGETIC COMBINATION OF ANALGETIC OPIATE AND CYCLOOOXYGENASE-2 INHIBITOR
SE9703693D0 (en) 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
ME00855B (en) 1997-12-03 2008-08-07 Merck & Co Inc Long acting injectable formulations containing hydrogenated castor oil
US6136804A (en) 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
US6184220B1 (en) 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
EP0945131A1 (en) 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Peroral drug suspension
EP0945134A1 (en) 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG New galenic formulations of meloxicam for oral administration
EP1082966A4 (en) 1998-05-15 2004-07-21 Wakamoto Pharma Co Ltd ANTI-INFLAMMATORY EYE DROPS
US6319519B2 (en) 1998-07-07 2001-11-20 Norton Healthcare Ltd. Anti-inflammatory pharmaceutical formulations
US6106862A (en) 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
DE69905380T2 (en) 1998-09-10 2003-11-27 Nycomed Danmark A/S, Roskilde PHARMACEUTICAL COMPOSITIONS WITH QUICK RELEASE OF ACTIVE SUBSTANCES
DE19847968A1 (en) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Separate storage of an active material and a solvent comprises a closure cap and a container, with a chamber attached to the unit.
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US6156349A (en) 1998-12-14 2000-12-05 Steinbach, Pylant And Herman, L.L.C. Method of treating HIV infection with suppository containing mammalian liver extract
US6183779B1 (en) 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
US6166012A (en) 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
US6552020B1 (en) 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
FR2798289B1 (en) 1999-09-15 2004-12-31 Cll Pharma QUICKLY DELITING MOUTH GALENIC FORMS AND THEIR PREPARATION METHOD
AU1548001A (en) 1999-11-24 2001-06-04 Wakamoto Pharmaceutical Co., Ltd. Ophthalmic aqueous preparation
US6685928B2 (en) 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
KR200182299Y1 (en) 1999-12-08 2000-05-15 장지일 Floss holder having floss case
IN191512B (en) 2000-01-21 2003-12-06 Panacea Biotech
DE10010123A1 (en) 2000-03-03 2001-09-20 Boehringer Ingelheim Int Needle-less injector for liquids comprises a tensioning system, an energy storing spring, a hollow piston in a cylinder, and a nozzle
CA2407335C (en) 2000-05-03 2010-08-03 Joe D'silva Process and device for producing liquid dosage formulations
WO2001087343A2 (en) 2000-05-15 2001-11-22 Merck Frosst Canada & Co. Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
DE10024752A1 (en) 2000-05-16 2001-11-29 Ben Pfeifer Composition for treating prostate diseases, especially inflammation, hyperplasia or cancer, comprises active agent solution containing dimethyl sulfoxide or hyaluronidase as diffusion promoter, applied using catheter
AU2001264729A1 (en) 2000-05-22 2001-12-03 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
DE10030345A1 (en) 2000-06-20 2002-01-10 Boehringer Ingelheim Vetmed Highly concentrated stable meloxicam solutions
DE10032132A1 (en) 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermal therapeutic system containing non-steroidal anti-inflammatory drugs with selective COX-2 inhibition
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
AU2001282886A1 (en) 2000-07-13 2002-01-30 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
ES2223209B1 (en) 2001-12-11 2005-10-01 Esteve Quimica, S.A. NEW CRYSTAL FORMS OF MELOXICAM AND PROCEDURES FOR PREPARATION AND INTERCONVERSION.
GB0022215D0 (en) 2000-09-11 2000-10-25 Boehringer Ingelheim Pharma Method for the treatment of thromboembolic disorders in patients with aspirin« resistance
DE10300323A1 (en) 2003-01-09 2004-10-14 Baxter Healthcare S.A. Safety container filled with a biologically active substance, especially a cytostatic agent, is at least partially coated
US20040204413A1 (en) 2001-01-26 2004-10-14 Joaquina Faour Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant
AU2002306868A1 (en) 2001-03-28 2002-10-15 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
US20020187187A1 (en) 2001-04-21 2002-12-12 Toshimitsu Ohki Fast disintegrating meloxicam tablet
EP1250921A1 (en) 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
ATE494363T1 (en) 2001-09-28 2011-01-15 Univ Brigham Young NEW CYCLOOXYGENASE VARIANTS AND METHODS OF USE
US20040253312A1 (en) 2001-09-28 2004-12-16 Sowden Harry S. Immediate release dosage form comprising shell having openings therein
DE10161077A1 (en) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Highly concentrated stable meloxicam solutions for needleless injection
EP1348436A1 (en) 2002-03-30 2003-10-01 Boehringer Ingelheim International GmbH Meloxicam suppositories
US20040001883A1 (en) 2002-03-30 2004-01-01 Boehringer Ingelheim International Gmbh Meloxicam suppositories
US20040024042A1 (en) 2002-04-02 2004-02-05 Vanderbilt University COX2 inhibition in the prevention and treatment of autosomal dominant polycystic kidney disease
DE10223013A1 (en) 2002-05-22 2003-12-04 Boehringer Ingelheim Int Use of meloxicam for the relief of organ injuries during organ surgery or transplantation
WO2004004776A1 (en) 2002-07-09 2004-01-15 B.M.R.A. Corporation B.V. Phamaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor
US20040037869A1 (en) 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
EP1542695A1 (en) 2002-09-17 2005-06-22 Nippon Boehringer Ingelheim Co., Ltd. Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer.
AU2003295336A1 (en) 2002-09-19 2004-04-08 Dennis A. Carson Use of etodoclac to treat hyperplasia
US20040171611A1 (en) 2002-09-30 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline acetic acid solvate of meloxicam
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
DE10250081A1 (en) 2002-10-25 2004-05-13 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
CA2413705A1 (en) 2002-12-06 2004-06-06 Raul Altman Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US20050197332A1 (en) 2002-12-10 2005-09-08 Boehringer Ingelheim International Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
US20040214753A1 (en) 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
DE10315702A1 (en) 2003-04-07 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of drug combinations for the treatment of benign prostatic hyperplasia or for the treatment of abacterial prostatitis
US20040198826A1 (en) 2003-04-07 2004-10-07 Boehringer Ingelheim International Gmbh Pharmaceutical combination for treating benign prostatic hyperplasia or for treating abacterial prostatitis
JP4018022B2 (en) 2003-04-10 2007-12-05 株式会社ホシモト Opening and closing handle device
WO2004103283A2 (en) 2003-05-14 2004-12-02 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
TW200505425A (en) 2003-05-29 2005-02-16 Schering Plough Ltd Compositions and method for treating infection in cattle and swine
WO2005004915A2 (en) 2003-07-09 2005-01-20 Boehringer Ingelheim International Gmbh Compositions comprising meloxicam
US20050038018A1 (en) 2003-07-09 2005-02-17 Boehringer Ingelheim International Gmbh Meloxicam compositions
US20050147664A1 (en) 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
CA2562305A1 (en) 2004-04-08 2005-10-20 Idd-Eal Manufacturing Company Limited Container for constituting a formulation in liquid form
DE102004021281A1 (en) 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam formulations in veterinary medicine
DE102004025324A1 (en) 2004-05-19 2005-12-08 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation for veterinary medicine, process for their preparation and their use
DE102004030409A1 (en) 2004-06-23 2006-01-26 Boehringer Ingelheim Vetmedica Gmbh New use of meloxicam in veterinary medicine
JP2008534473A (en) 2005-03-23 2008-08-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Composition comprising a thromboxane receptor antagonist and a thromboxane synthase inhibitor combination and a COX-2 inhibitor
CA2623201A1 (en) 2005-09-30 2007-04-12 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing meloxicam
US20070187405A1 (en) 2006-01-23 2007-08-16 Pujara Chetan P Container for compositions containing cefdinir
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
JP4321624B2 (en) 2007-05-21 2009-08-26 株式会社デンソー Semiconductor device drive circuit
FR2917381B1 (en) 2007-06-15 2009-10-16 Ceva Sante Animale Sa MULTILAYER PLASTIC PACKAGING FOR PRESERVING A PHARMACEUTICAL COMPOSITION
US8486043B2 (en) 2007-10-12 2013-07-16 Map Pharmaceuticals, Inc. Inhalation drug delivery
GB0724707D0 (en) 2007-12-19 2008-01-30 Burke Michael H A process for the preparation of an orally administered unit dose tablet
ES3037313T3 (en) 2009-10-12 2025-09-30 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US20110218191A1 (en) 2010-03-03 2011-09-08 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long term-treatment of kidney disorders in cats
MX2012010077A (en) 2010-03-03 2012-09-12 Boehringer Ingelheim Vetmed Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats.
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007135505A2 (en) * 2006-05-18 2007-11-29 Formevet S.P.A. Veterinary pharmaceutical compositions for the treatment of pain and inflammation
WO2008113149A2 (en) * 2007-03-22 2008-09-25 Ouro Fino Participações E Empreendimentos Ltda Observations where certain claims were found unsearchable

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLARKE, S.P & BENNETT, D.: "Feline osteoarthritis: a prospective study of 28 cases", JOURNAL OF SMALL ANIMAL PRACTICE, vol. 47, August 2006 (2006-08-01), pages 439 - 445, XP002587628 *
CLARKE; BENNETT: "Feline osterarthritis: a prospective study of 28 cases", JOURNAL OF SMALL ANIMAL PRACTICE, vol. 47, 2006, pages 439 - 445
GUNEW ET AL.: "Long-term safety, efficacy and palatability of oral meloxicam at 0.01 - 0.03 mg/ kg for treatment of osteoarthritic pain in cats", JOURNAL OF FELINE MEDICINE AND SURGERY, vol. 10, 2008, pages 235 - 241
GUNEW M N ET AL: "Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03mg/kg for treatment of osteoarthritic pain in cats", JOURNAL OF FELINE MEDICINE AND SURGERY, WB SAUNDERS, LONDON, GB LNKD- DOI:10.1016/J.JFMS.2007.10.007, vol. 10, no. 3, 1 July 2008 (2008-07-01), pages 235 - 241, XP022690365, ISSN: 1098-612X, [retrieved on 20080428] *
ROBSON M ET AL: "Intrinsic acute renal failure (ARF) associated with non-steroidal anti-inflammatory drug (NSAId) use in juvenile cats undergoing routine desexing-16 cases 1998-2005", JOURNAL OF VETERINARY INTERNAL MEDICINE, LIPPINCOTT, PHILADELPHIA, US, vol. 20, no. 3, 3 May 2006 (2006-05-03), pages 740, XP009134517, ISSN: 0891-6640 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956288B2 (en) 2000-06-20 2018-05-01 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions
US9066955B2 (en) 2002-10-25 2015-06-30 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US10548901B2 (en) 2004-02-23 2020-02-04 Boehringer Ingelheim Vetmedica Gmbh Meloxicam for the treatment of respiratory diseases in pigs
US11083731B2 (en) 2004-02-23 2021-08-10 Boehringer Ingelheim Vetmedica Gmbh Meloxicam for the treatment of respiratory diseases in pigs
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9943486B2 (en) 2010-05-05 2018-04-17 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets

Also Published As

Publication number Publication date
KR20130037237A (en) 2013-04-15
CA2791805A1 (en) 2011-09-09
BR112012022073A2 (en) 2017-10-31
MX2012010077A (en) 2012-09-12
US20130035330A1 (en) 2013-02-07
SG183846A1 (en) 2012-10-30
US9149480B2 (en) 2015-10-06
AU2010347598A1 (en) 2012-09-13
AU2010347598B2 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
Trouchon et al. A review of enrofloxacin for veterinary use
Carretero et al. Pharmacokinetics of marbofloxacin in mature horses after single intravenous and intramuscular administration
Wanstrath et al. Evaluation of a single intra‐articular injection of autologous protein solution for treatment of osteoarthritis in a canine population
Flôr et al. Tramadol plus metamizole combined or not with anti-inflammatory drugs is clinically effective for moderate to severe chronic pain treatment in cancer patients
Sidhu et al. PK–PD integration and modeling of marbofloxacin in sheep
Loeffler et al. Antimicrobial use guidelines for canine pyoderma by the International Society for Companion Animal Infectious Diseases (ISCAID)
US9149480B2 (en) Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
Sykes et al. Administration of trimethoprim-sulphadimidine does not improve healing of glandular gastric ulceration in horses receiving omeprazole: a randomised, blinded, clinical study
JP2013521253A (en) Use of meloxicam for long-term treatment of kidney injury in cats
Mansa et al. Long‐term treatment with carprofen of 805 dogs with osteoarthritis
Peterson et al. Effects of meloxicam on severity of lameness and other clinical signs of osteoarthritis in dogs
Beccar‐Varela et al. Effect of experimentally induced synovitis on amikacin concentrations after intravenous regional limb perfusion
Lallemand et al. Pharmacokinetics, pharmacodynamics and local tolerance at injection site of marbofloxacin administered by regional intravenous limb perfusion in standing horses
Denerolle et al. Organic diseases mimicking acral lick dermatitis in six dogs
Devine et al. Pharmacokinetics of intramuscularly administered morphine in horses
CN113271949A (en) Sildenafil for the treatment of osteoarthritis
JP2017531042A (en) Pyrazoline derived compounds and their use in weekly dosing regimens for inflammation and pain from degenerative joint disease in mammals
Schleining et al. Liposome‐based diclofenac for the treatment of inflammation in an acute synovitis model in horses
Wright Navicular suspensory desmotomy in the treatment of navicular disease: technique and preliminary results
White et al. Efficacy of intramuscular chondroitin sulfate and compounded acetyl-d-glucosamine in a positive controlled study of equine carpitis
Kilcoyne et al. Morphine synovial fluid concentrations after intravenous regional limb perfusion in horses during standing sedation
WO2018200411A1 (en) Methods for inducing chondrogenesis
Enomoto et al. Prevalence of radiographic osteoarthritis and associated clinical signs in young dogs
Bienhoff et al. Efficacy and safety of deracoxib for the control of postoperative pain and inflammation associated with dental surgery in dogs
EP3996705A1 (en) Telmisartan for the treatment of chronic kidney disease in dogs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10706643

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010347598

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2791805

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012555306

Country of ref document: JP

Ref document number: MX/A/2012/010077

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012002436

Country of ref document: CL

ENP Entry into the national phase

Ref document number: 2010347598

Country of ref document: AU

Date of ref document: 20100303

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20127025827

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13581661

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 10706643

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012022073

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012022073

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120831